Gedeon Richter Looks to Dendrite to Enhance its Sales Force Effectiveness Solution

Dendrite International, Inc., (NASDAQ: DRTE) a leadingprovider of pharmaceutical industry solutions, today announced theexpansion of its relationship with Gedeon Richter, a leadingpharmaceutical company in Central and Eastern Europe. Dendrite willprovide Gedeon Richter's Russian Federation based division with itssales force effectiveness (SFE) solution, expanding on a previousagreement to enhance sales force effectiveness for the company'sdivisions in Poland, Romania and the Czech Republic. With the additionof this division, Dendrite's SFE solution will now assist a total of1000 of Gedeon Richter's representatives with core sales forceeffectiveness enabling functions, including call reporting, targeting,advanced data sharing, data analysis and decision support, eventmanagement, territory planning and scheduling.

"We required a solution that gave us the ability to optimize salesactivities across sales forces in multiple countries, with theversatility to adapt to our growing business. Dendrite was an obviouschoice because it offered the most flexible and scalable solution --supporting strategic sales forces of under 100 users to more than1000. Furthermore, since the solution can be deployed in multiplecountries, it gives us the ability to easily share information on acommon platform across all of our Central and Eastern Europeanregions," said Deputy Commercial Director Beata Taligas at GedeonRichter's Budapest headquarters.

Designed by Dendrite's experts specifically to enhance usabilityfor pharmaceutical industry sales forces, Dendrite's SFE solutionoptimizes and coordinates promotional activities across sales teams,improves communications, and streamlines new product launches.

"We are delighted to have extended our offering to Gedeon Richter,at a time during which the industry is increasingly recognizing thevalue of solutions that are easy to use and based on actual businessprocess flow. Dendrite SFE solutions are built specifically for thepharmaceutical industry and we look forward to continuing tostrengthen the relationship with Gedeon through adding valuablesupport," said Mario Mauri, president, Dendrite Europe.

About Dendrite

Founded in 1986, Dendrite International (NASDAQ: DRTE) enablessales, marketing, clinical and compliance solutions for the global,pharmaceutical industry. The Company's clients are located in morethan 50 countries and include the world's top 20 pharmaceuticalcompanies. For more information, please visit www.dendrite.com.

About Gedeon Richter

Gedeon Richter Ltd carries out research, development, manufactureand marketing of human finished drugs, active substances andintermediates. The Company manufactures about one hundred kinds ofpharmaceuticals in more than 170 presentations. Among its products areoriginal, generic and licensed preparations. Products cover numeroustherapeutic areas, with special emphasis on the production anddevelopment of drugs for the central nervous system, as well asanti-ulcer agents, cardiovascular and gastrointestinal preparationsand oral contraceptives.

Note: Dendrite is a registered trademark of DendriteInternational, Inc.

This document may contain forward-looking statements that may beidentified by such forward-looking terminology as "expect," "believe,""anticipate," "will," "intend," "plan," "target," "outlook,""guidance," and similar statements or variations. Such forward-lookingstatements are based on our current expectations, estimates,assumptions and projections and involve significant risks anduncertainties, including risks which may result from our dependence onthe pharmaceutical industry; fluctuations in quarterly revenues due tolengthy sales and implementation cycles for certain of our solutions;our fixed expenses in relation to fluctuating revenues and variationsin customers' budget cycles; dependence on certain major customers;changes in demand for our products and services attributable to anyweakness experienced in the economy or mergers, acquisitions andconsolidations in the pharmaceutical industry; successful and timelydevelopment and introduction of new products and versions; rapidtechnological changes; increased competition; internationaloperations; integrating the entities we acquire; our ability toeffectively manage our growth; the protection of our proprietarytechnology; our ability to compete in the Internet-related productsand services market; the continued demand for Internet-relatedproducts and services; the ability of our third party vendors torespond to technological change; our ability to maintain ourrelationships with third-party vendors; less favorable thananticipated results from strategic relationships; dependence of datasolutions on strategic relationships; events which may affect the U.S.and world economies; and catastrophic events which could negativelyaffect our information technology infrastructure. Other importantfactors that should be reviewed and carefully considered are includedin the company's 10-K, 10-Qs, and other reports filed with the SEC.Actual results may differ materially. The company assumes noobligation for updating any such forward-looking statements to reflectactual results, changes in assumptions or other changes affecting suchforward-looking statements.